March 2016 Member News & Networking

Feb 23, 2016

Daniel V.T. Catenacci, MD, coauthored a study in which it was found that blood samples collected from the portal vein provided more information about a patient’s pancreatic cancer than samples collected from a more accessible vein in the arm. Dr. Catenacci believes the findings from this study “may help predict who will benefit from aggressive therapy before surgery, who is most at risk for a recurrence after the operation, and even who will not benefit from surgery at all.”


Jessica Clague DeHart, PhD, MPH, is the lead author on a City of Hope study, presented at the 2015 San Antonio Breast Cancer Symposium, which found that nearly all women who have been recently diagnosed with breast cancer reported “treatment-related” symptoms, including hot flashes and fatigue, prior to receiving any treatment. Dr. DeHart is an Assistant Professor of Population Sciences at City of Hope.


Randall F. Holcombe, MD, MBA, and other researchers have identified several nontoxic chemicals found in plants and foods that may improve patient outcomes in some cancers. Their review was published in Seminars in Cancer Biology. Dr. Holcombe was invited to participate in this initiative because of his previous research of resveratrol, a compound found in grapes and red wine, and genistein, a soy-derived nutrient protein for the prevention and treatment of colon cancer.

V. Craig Jordan, OBE, DSc, PhD, Professor of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, received the 2015 Sir James Black Award for Contributions to Drug Discovery from the British Pharmacological Society. He is recognized for his discoveries of important principles for drug treatment and his pioneering research on selective estrogen receptor modulators.


Mia Levy, MD, has been named Director of Cancer Health Information and Strategy at Vanderbilt- Ingram Cancer Center, a new management post that will expand her leadership role. In this newly created role, Dr. Levy will oversee the development of new informatics tools to support the next generation of precision cancer medicine, data analytics, and cancer care coordination.


Olufunmilayo I. Olopade, MBBS, FACP, FASCO, is one of four primary investigators in an ongoing study, which commenced in 2003, focusing on the role of BRCA1 and BRCA2 mutations in the occurrence of early-onset breast cancer in women of African descent, particularly women in Nigeria and Senegal.


ASCO Chief Medical Officer Richard L. Schilsky, MD, FACP, FASCO, has been appointed to The New England Journal of Medicine’s Editorial Board. He will serve a 3-year term alongside 15 other members chosen to contribute a “rich source of ideas and advice about the path the Journal should take in the future.” In this role, Dr. Schilsky will work with fellow board members to review papers, provide advice to editors, and participate in board meetings.


Unum Therapeutics named Michael J. Vasconcelles, MD, as the company’s Chief Medical Officer. He is responsible for defining the strategic vision and leading execution of the company’s clinical efforts to develop its universal Antibody-Coupled T-cell Receptor (ACTR) product.


Sidney Winawer, MD, co-chaired an advisory committee on the NYC Citywide Colon Cancer Control (C5) Coalition, which increased the rate of colorectal cancer screening rates in New York City from 42% to 62% over 4 years, from 2003 to 2007. In 2014, the screening rate for eligible recipients in New York City reached nearly 70%.



In Memoriam

Vincent Albo, MD
Richard F. Bakemeier, MD
Candy Corey, MD
Tarit Kanti Dutta, MD
David J. Gnarra, MD
Edda L. Gomez-Panzani, MD
Mark R. Green, MD
Wolfgang Hinkelbein, MD
Robert Stephen Huebner, MD
Richard J. Kaufman, MD
Dennis F. Moore, Sr., MD
Jacob C. Ninan, MD, FACP
Victor L. Randolph, MD
C. William Reiquam, MD
David J. Russin
Gerhard M. Stauder, PhD
Ellen L. Stovall, FASCO*
Hemachandra Venkatesh, MD

Back to Top